Patient-reported Rating of Gastrointestinal Adverse Effects During Treatment of Type 2 Diabetes With the Once-Daily Human GLP-1 Analogue, Liraglutide

Diabetes Obes Metab. 2008 Jul;10(7):593-6. doi: 10.1111/j.1463-1326.2008.00861.x. Epub 2008 Apr 22.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Female
  • Gastrointestinal Diseases / chemically induced*
  • Glucagon-Like Peptide 1 / adverse effects
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Humans
  • Incretins / adverse effects*
  • Liraglutide
  • Male
  • Middle Aged

Substances

  • Incretins
  • Liraglutide
  • Glucagon-Like Peptide 1